Clinical trial
Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia…
NCT00121030 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00121030 |
|---|---|
| Title | Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy |
| Official title | An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Patients With Gynecological Malignancies Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gynecological Malignancies, Genital Neoplasms, Female, Anemia |
| Intervention type | Drug |
| Interventions | darbepoetin alfa, recombinant human erythropoietin (rHuEPO) |
| Start date | Oct 1, 2002 |
| Completion | Dec 1, 2003 |
| First posted | Jul 21, 2005 |
| Last update posted | Dec 24, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: